Transgenic overexpression of beta(2)-adrenergic receptors in airway smooth muscle alters myocyte function and ablates bronchial hyperreactivity.
beta(2)-Adrenergic receptors (beta(2)AR) act to relax airway smooth muscle and can serve to counteract hyperresponsiveness, although the effect may not be ablative even in the presence of exogenous agonist. Within this signaling cascade that ultimately transduces smooth muscle relaxation, a significant "spare receptor" pool has been hypothesized to be present in the airway. In order to modify the relationship between beta(2)AR and downstream effectors, transgenic mice (TG) were created overexpressing beta(2)AR approximately 75-fold in airway smooth muscle using a mouse smooth muscle alpha-actin promoter. While >90% of these receptors were expressed on the smooth muscle cell surface, the percentage of receptors able to form the agonist-promoted high affinity complex was less than that found with nontransgenic (NTG) cells (R(H) = 18 versus 36%). Nevertheless, beta(2)AR signaling was found to be enhanced. Intact airway smooth muscle cells from TG had basal cAMP levels that were greater than NTG cells. A marked increase in agonist-stimulated cAMP levels was found in the TG ( approximately 200% stimulation over basal) compared with NTG ( approximately 50% over basal) cells. Adenylyl cyclase studies gave similar results and also showed a 10-fold lower EC(50) for TG cells. Tracheal rings from TG mice that were precontracted with acetylcholine had an enhanced responsiveness (relaxation) to beta-agonist, with a 60-fold decrease in the ED(50), indicating that the enhanced signaling imposed by overexpression results in an increase in the coordinated function of the intact airway cells. In vivo studies showed a significantly blunted airway resistance response to the inhaled bronchoconstrictor methacholine in the TG mice. Indeed, with beta-agonist pretreatment, the TG mice displayed no response whatsoever to methacholine. These results are consistent with beta(2)AR being the limiting factor in the transduction system. Increases in the initial component of this transduction system (the beta(2)AR) are sufficient to markedly alter signaling and airway smooth muscle function to the extent that bronchial hyperresponsiveness is ablated, consistent with an anti-asthma phenotype.
McGraw
D W
DW
Department of Medicine, University of Cincinnati College of Medicine, Cincinnati Ohio 45267, USA.
Forbes
S L
SL
Kramer
L A
LA
Witte
D P
DP
Fortner
C N
CN
Paul
R J
RJ
Liggett
S B
SB
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D016535:Bronchial Hyperreactivity / Q000503:physiopathology*; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000096:biosynthesis; D017403:In Situ Hybridization; D051379:Mice; D008822:Mice, Transgenic; D009130:Muscle, Smooth / Q000502:physiology*; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics* / Q000502:physiology; D012260:Ribonucleases / Q000378:metabolism; D015398:Signal Transduction; D014132:Trachea; D019076:Transgenes
D018343:Receptors, Adrenergic, beta-2; D000242:Cyclic AMP; D012260:Ribonucleases; D000262:Adenylyl Cyclases